뒤로
Evommune Inc(EVMN) 가격
EVMN 주가 차트
EVMN 재무
Evommune Inc
$31.2
-1.17%
$-0.37
종가: Feb 17, 16:00:00 GMT-5
$30.23
-3.1%
$-0.96
애프터마켓: Feb 17, 18:02:05 GMT-5
수입
자산 및 부채 명세서
현금 흐름
연간
분기별
EVMN 소득
미화 수백만 달러. 회계 연도는 2월부터 1월까지입니다.
Follow-Up Questions
¿Cuáles son los estados financieros clave de Evommune Inc?
¿Cuáles son los ratios financieros clave para EVMN?
¿Cómo se desglosan los ingresos de Evommune Inc por segmento o geografía?
¿Es rentable Evommune Inc?
¿Tiene Evommune Inc alguna deuda?
¿Cuántas acciones en circulación tiene Evommune Inc?
주요 통계
이전 종가
$31.57
시가
$31.35
일일 범위
$29.46 - $33.1
52주 범위
$13.88 - $33.2
거래량
489.9K
평균 거래량
543.3K
EPS(TTM)
-5.08
배당수익률
--
시가총액
$952.8M
EVMN란 무엇인가요?
Evommune, Inc. is a clinical-stage biotechnology company. The company is headquartered in Palo Alto, California and currently employs 45 full-time employees. The company went IPO on 2025-11-06. Its initial clinical development programs are focusing on chronic spontaneous urticaria (CSU), atopic dermatitis (AD) and ulcerative colitis (UC). Its product candidates include EVO756 and EVO301. The firm's advanced clinical-stage product candidate, EVO756, is a potent and highly selective oral small molecule antagonist of MRGPRX2, a receptor predominantly found on mast cells and peripheral sensory neurons, which is initially being evaluated in Phase II trials for the treatment of CSU and AD. The firm's second clinical-stage product candidate, EVO301, is a long-acting fusion protein consisting of an IL-18 binding protein (BP) and an anti-serum albumin Fab-associated (SAFA) domain, which is being evaluated in Phase II trials for the treatment of AD and UC.